




The relative strengths and weaknesses of Oncomed Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncomed Pharmaceuticals Inc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 2.6% points. The greatest weakness of Oncomed Pharmaceuticals Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 135% points.

The company's Economic Capital Ratio, given in the ranking table, is 140%, being 123% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	231,255
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	52,641
Liabilities, Non-Current	0
Other Assets	1,807
Other Compr. Net Income	37
Other Expenses	20
Other Liabilities	181,695
Other Net Income	170
Other Revenues	25,899
Property and Equipment	4,825
Research and Development	92,873
Selling, General and Administrative Expense	18,583

Output Variable	Value in 1000 USD
Assets	237,887
Liabilities	234,336
Expenses	111,476
Revenues	25,899
Stockholders Equity	3,551
Net Income	-85,407
Comprehensive Net Income	-85,388
BaseVar	304,902
ECR before LimitedLiability	-33%
Economic Capital Ratio	140%